Humacyte is trading 7.4% down at $0.66 ahead of its scheduled second-quarter 2026 results.
- Results and a business update are scheduled for 8:00 a.m. Eastern on August 12.
- Estimates call for approximately $1.12 million in revenue and a $0.10-per-share loss.
- Shares fell 4.63% to $0.71 during the August 11 session; no confirmed results or separate overnight catalyst were identified before 7:15 a.m.